The REMS program for the ERA drug class was established due to the risk of embryofetal toxicity seen from animal studies.

In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, highlights first-time ...

Abstract—The 21-amino acid peptide endothelin-1 (ET-1) is the predominant isoform of the endothelin peptide family, which includes ET-2, ET-3, and ET-4. It exerts various biological effects, including ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

The CDE of China's NMPA has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second BTD.